Abstract
Breast cancer remains the most common cancer among women, with an estimated 212,920 new cases and 40,970 deaths in the United States in 2006. The present work extends the studies of nanoparticles targeted to the luteinizing hormone-releasing hormone (LHRH) receptor which is overexpressed in breast, ovarian, endometrial and prostate cancer cells. In contrast, LHRH receptors are not expressed, or expressed at a low level in most visceral organs. In our studies, we conjugated Fe3O4 nanoparticles (20–30 nm) with [D-Trp6]LHRH (Triptorelin), a decapeptide analog of LHRH currently used for treatment of sex-hormone-dependent tumors. Conjugation of [D-Trp6]LHRH to Fe3O4 particles retained its binding affinity and biological activity for the LHRH receptor. Treatment of two separate breast tumor cell lines (MCF-7 and MDA-MB231) with these conjugated nanoparticles resulted in 95–98% cell death and loss of viability within 24 h whereas no change in cell proliferation or cell apoptosis was observed in cells treated with equal amounts of either [D-Trp6]LHRH or unconjugated Fe3O4 nanoparticles. These studies provide critical and important information regarding use of LHRH receptor targeted therapy for breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A. Jemal, R. Siegel, E. Ward et al. Cancer statistics, 2006. CA: a Cancer J Clin 2006; 56(2): 106–130
A.M. Bajo, A.V. Schally, G, Halmos et al. Targeted doxorubicin containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 2003; 9: 3742–3748
S.S. Kakar, M.T. Malik, S.J. Winters et al. Gonadotropin-releasing hormone receptors: structure, expression, and signaling transduction. Vit Horm 2004; 69: 151–207
A. Nagy, A.V. Schally. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005; 73(5): 851–859
S.S. Dharap, Y. Wang, P. Chandna et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Nat Acad Sci USA 2005; 102(36): 12962–12967
J. Zhou, C. Leuschner, C. Kumar et al. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases. Biomaterials 2006; 27(9): 2001–2008
C. Leuschner, C. Kumar, M. Urbina et al. The use of ligand conjugated supermagnetic iron oxide nanoparticles (SPION) for early detection of metastasis. In INST Naotech Tech Proc 1005; 1: 5–6
M. Islam, L. Fu, M. Su et al. Novel one-step synthesis of amine-stabilized aqueous colloidal gold nanoparticles. J Material Chem 2004; 14; 1795–1797
S.S. Kakar, L.C. Musgrove, D.C. Dever et al. Cloning, sequencing, and expression of human gonadotropin-releasing hormone (GnRH) receptor, Biochem Biophys Res Commun 1992; 189: 289–295
10. S.S. Kakar, S.J. Winters, W. Zacharias et al. Identification of distinct gene expression profiles associated with treatment of LbetaT2 cells with gonadotropin-releasing hormone agonist using microarray analysis. Gene 2003; 308: 67–77
P. Thomas, P.L. Mellon, J. Turgeon et al. The L beta T2 clonal gonadotrope: a model for single cell studies of endocrine cell secretion. Endocrinology 1996; 137: 2979–2989
G.Y. Bedecarrats, K.D. Linher, J.A. Janovick et al. Four naturally occurring mutations in the human GnRH receptor affect ligand binding and receptor function. Mol Cell Endocrin 2003; 205(1–2), 51–64
A. Mangia, S. Tommasi, S.J. Reshkin et al. Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of imunohistochemical, radioligand and Western blot analyses, Oncol Rep 2002; 9(5): 1127–1132
T. Moriya, T. Suzuki, M. Pilichowska et al. Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma. Pathol Int 2001; 51(5): 333–337
M. W. Qian, J.W. Eaton. Iron translocation by free fatty acids, Am J Path 1991; 139(6): 1425–1434
S.S. Kakar. Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity Gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide). Cancer Res 1998; 58(20): 4558–4560
Z. Yu, H.L. Persson, J.W. Eaton et al. Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Rad Biol Med 2003; 34(10): 1243–1252
H.L. Persson, Z. Yu, O. Tirosh et al. Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Rad Biol Med 2004; 34(10): 1295–1305
U.T. Brunk, J. Neuzil, J.W. Eaton. Lysosomal involvement in apoptosis, Redox Rep 2001;6(2): 91–97
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this paper
Cite this paper
Kakar, S., Jin, H., Hong, B., Eaton, J., Kang, K.A. (2008). LHRH Receptor Targeted Therapy for Breast Cancer. In: Kang, K.A., Harrison, D.K., Bruley, D.F. (eds) Oxygen Transport to Tissue XXIX. Advances In Experimental Medicine And Biology, vol 614. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-74911-2_32
Download citation
DOI: https://doi.org/10.1007/978-0-387-74911-2_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-74910-5
Online ISBN: 978-0-387-74911-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)